Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Public ClinicalTrials.gov record NCT03801902. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced). Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Oleclumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD73, which is found on some types of tumor cells. Oleclumab may block CD73 and help the immune system kill tumor cells. It is not yet known whether adding durvalumab to ACRT or adding monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy will work better in treating patients with non-small cell lung cancer.
Study identification
- NCT ID
- NCT03801902
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 26 participants
Conditions and interventions
Conditions
Interventions
- Accelerated Hypofractionated Radiation Therapy Radiation
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Durvalumab Biological
- Magnetic Resonance Imaging of the Brain with and without Contrast Procedure
- Monalizumab Biological
- Oleclumab Biological
- Radiation Therapy Radiation
Radiation · Procedure · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2019 (Actual)
- Primary completion
- Oct 26, 2021 (Actual)
- Completion
- Sep 4, 2025 (Actual)
- Last update posted
- Sep 23, 2025
2019 – 2025
United States locations
- U.S. sites
- 56
- U.S. states
- 16
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Grady Health System | Atlanta | Georgia | 30303 | — |
| Emory University Hospital Midtown | Atlanta | Georgia | 30308 | — |
| Emory University Hospital/Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Emory Saint Joseph's Hospital | Atlanta | Georgia | 30342 | — |
| Augusta University Medical Center | Augusta | Georgia | 30912 | — |
| Saint Alphonsus Cancer Care Center-Boise | Boise | Idaho | 83706 | — |
| Saint Alphonsus Cancer Care Center-Caldwell | Caldwell | Idaho | 83605 | — |
| Saint Alphonsus Cancer Care Center-Nampa | Nampa | Idaho | 83687 | — |
| University of Kansas Cancer Center-West | Kansas City | Kansas | 66112 | — |
| University of Kansas Cancer Center | Kansas City | Kansas | 66160 | — |
| University of Kansas Cancer Center-Overland Park | Overland Park | Kansas | 66210 | — |
| University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas | 66205 | — |
| Saint Elizabeth Healthcare Edgewood | Edgewood | Kentucky | 41017 | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| UM Upper Chesapeake Medical Center | Bel Air | Maryland | 21014 | — |
| Central Maryland Radiation Oncology in Howard County | Columbia | Maryland | 21044 | — |
| UM Baltimore Washington Medical Center/Tate Cancer Center | Glen Burnie | Maryland | 21061 | — |
| McLaren Cancer Institute-Bay City | Bay City | Michigan | 48706 | — |
| McLaren Cancer Institute-Clarkston | Clarkston | Michigan | 48346 | — |
| Michigan Healthcare Professionals Clarkston | Clarkston | Michigan | 48346 | — |
| Wayne State University/Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Michigan Healthcare Professionals Farmington | Farmington Hills | Michigan | 48334 | — |
| Weisberg Cancer Treatment Center | Farmington Hills | Michigan | 48334 | — |
| McLaren Cancer Institute-Flint | Flint | Michigan | 48532 | — |
| Singh and Arora Hematology Oncology PC | Flint | Michigan | 48532 | — |
| Karmanos Cancer Institute at McLaren Greater Lansing | Lansing | Michigan | 48910 | — |
| Mid-Michigan Physicians-Lansing | Lansing | Michigan | 48912 | — |
| McLaren Cancer Institute-Lapeer Region | Lapeer | Michigan | 48446 | — |
| McLaren Cancer Institute-Macomb | Mount Clemens | Michigan | 48043 | — |
| McLaren Cancer Institute-Northern Michigan | Petoskey | Michigan | 49770 | — |
| McLaren-Port Huron | Port Huron | Michigan | 48060 | — |
| Michigan Healthcare Professionals Troy | Troy | Michigan | 48098 | — |
| Siteman Cancer Center at Saint Peters Hospital | City of Saint Peters | Missouri | 63376 | — |
| Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri | 63141 | — |
| University of Kansas Cancer Center - North | Kansas City | Missouri | 64154 | — |
| University of Kansas Cancer Center - Lee's Summit | Lee's Summit | Missouri | 64064 | — |
| University of Kansas Cancer Center at North Kansas City Hospital | North Kansas City | Missouri | 64116 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Siteman Cancer Center-South County | St Louis | Missouri | 63129 | — |
| Siteman Cancer Center at Christian Hospital | St Louis | Missouri | 63136 | — |
| Benefis Sletten Cancer Institute | Great Falls | Montana | 59405 | — |
| Logan Health Medical Center | Kalispell | Montana | 59901 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Legacy Mount Hood Medical Center | Gresham | Oregon | 97030 | — |
| Legacy Good Samaritan Hospital and Medical Center | Portland | Oregon | 97210 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | — |
| MD Anderson in The Woodlands | Conroe | Texas | 77384 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| MD Anderson West Houston | Houston | Texas | 77079 | — |
| MD Anderson League City | League City | Texas | 77573 | — |
| MD Anderson in Sugar Land | Sugar Land | Texas | 77478 | — |
| Legacy Salmon Creek Hospital | Vancouver | Washington | 98686 | — |
| West Virginia University Healthcare | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03801902, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03801902 live on ClinicalTrials.gov.